Anvisa publishes the list of active ingredients of medicines with registration requests under analysis
We must support Anvisa
Post-registration of medicines – opportunities and challenges
GGBIO task force: solution or palliative?
Anvisa: 25 years with many stories to tell
Anvisa's General Management of Medicines releases the 2023 Management Report
Real-world studies for drug registration: ANVISA guidelines
Find out about Anvisa's priorities for the next biennium
RDC 753 - New Regulatory Framework for the Registration of Synthetic Drugs.
WHAT ARE THE STEPS FOR OBTAINING AUTHORIZATION FOR CLINICAL STUDIES IN BRAZIL?
Important circumstances for the submission of drug registration in Brazil
What is the purpose of registration submission guide, based on data from scientific literature?
What are the main differences between the ICH guides and the ANVISA requirements?
ANVISA – Post-pandemic challenges and perspectives.
Clinical research in Brazil – New horizons, new challenges
ANVISA has just published the new version of the Cadifa Manual, but what were the main changes?
Unraveling the Abbreviated Development Path
Publication of the Public Consultation for the review of RDC 200 - what is new?
NEW REGULATORY FRAMEWORK OF API
